Provided by Tiger Trade Technology Pte. Ltd.

First Trust Nasdaq Pharmaceuticals ETF

40.49
-0.2400-0.59%
Volume:11.06K
Turnover:448.33K
Market Cap:1.04B
PE:- -
High:40.64
Open:40.57
Low:40.42
Close:40.73
52wk High:43.52
52wk Low:28.77
Shares:25.65M
Float Shares:25.65M
Volume Ratio:2.80
T/O Rate:0.04%
Dividend:0.29
Dividend Rate:0.71%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Leerink Downgrades Bristol Myers, Flags Pipeline Risks

Reuters
·
1 hour ago

Immunome Issues 4,425,487 Shares to Bristol-Myers Squibb in Unregistered Sale

Reuters
·
1 hour ago

Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins

THOMSON REUTERS
·
1 hour ago

Bristol-Myers Squibb Company : Leerink Partners Cuts to Market Perform from Outperform; Cuts Target Price to $59 from $73

THOMSON REUTERS
·
1 hour ago

Eli Lilly Presents New Ebglyss Data from Phase 3 ADorable-1 Pediatric Atopic Dermatitis Study at Fall Clinical 2026

Reuters
·
2 hours ago

JPMorgan Adjusts Price Target on Merck & Co. to $165 From $150, Maintains Overweight Rating

MT Newswires Live
·
2 hours ago

Eli Lilly & Co (LLY) Gets a Buy from RBC Capital

TIPRANKS
·
Oct 03

Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 03

AbbVie Joins US Government Pilot to Test Drug Discount Rebates

Reuters
·
Oct 03

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 03

Abbvie-from Jan 1, 2027, Covered Entities to Submit Claims to GET 340B Pricing Through Beacon on 340B-Eligible Dispenses of Imbruvica, Linzess,Vraylar

THOMSON REUTERS
·
Oct 03

Abbvie - Approved to Participate in Federal 340B Rebate Model Pilot Program

THOMSON REUTERS
·
Oct 03

Former Eli Lilly Exec Sells Wyoming Estate for Close to $39.5 Million

Dow Jones
·
Oct 03

Why Medtronic's $4 Billion MiniMed Exchange Offer is Losing Its Allure

Dow Jones
·
Oct 03

Eli Lilly announces FDA approves additional indication for Jaypirca

TIPRANKS
·
Oct 03

Lilly Says FDA Approves Expanded First-Line Cll/sll Use for Jaypirca

Reuters
·
Oct 03

Lilly's Jaypirca (Pirtobrutinib), the First-and-Only Approved Non-Covalent Btk Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated Cll/Sll

THOMSON REUTERS
·
Oct 03

Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says

MT Newswires Live
·
Oct 03

AbbVie’s Venetoclax AML Study in Greece: What the Latest Update Means for Investors

TIPRANKS
·
Oct 03

Perspective Therapeutics [212Pb]VMT01 Melanoma Trial Data Set for SITC 2026 Presentation

Reuters
·
Oct 02